Home	Fast Track My Amedeo FAQ About	Flying Publisher
Fast Track	FPG #8: Alternative Treatments in Psychiatry FPG #7: Critical Care in Neurology	Free Medical Books

Malignant Melanoma

Free Subscription Articles published in Br J Cancer Retrieve available abstracts of 49 articles: HTML format Text format

Single Articles

January 2012
1. WALDMANN A , Nolte S, Weinstock MA, Breitbart EW, et al
   Skin cancer screening participation and impact on melanoma incidence in Germany - an observational study on incidence trends in regions with and without population-based screening.
   Br J Cancer. 2012 Jan 31. doi: 10.1038/bjc.2012.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   
2. SAKAIZAWA K , Goto Y, Kiniwa Y, Uchiyama A, et al
   Mutation analysis of BRAF and KIT in circulating melanoma cells at the single cell level.
   Br J Cancer. 2012 Jan 26. doi: 10.1038/bjc.2012.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   
3. XU Y , Brenn T, Brown ER, Doherty V, et al
   Differential expression of microRNAs during melanoma progression: miR-200c, miR-205 and miR-211 are downregulated in melanoma and act as tumour suppressors.
   Br J Cancer. 2012 Jan 5. doi: 10.1038/bjc.2011.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   December 2011
4. PARKIN DM , Mesher D, Sasieni P
   13. Cancers attributable to solar (ultraviolet) radiation exposure in the UK in 2010.
   Br J Cancer. 2011;105 Suppl 2:S66-9.
   PubMed     Text format     Related articles   
   
   
   
   November 2011
5. ALGAZI AP , Weber JS, Andrews SC, Urbas P, et al
   Phase I clinical trial of the Src inhibitor dasatinib with dacarbazine in metastatic melanoma.
   Br J Cancer. 2011 Nov 29. doi: 10.1038/bjc.2011.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   
6. JANJETOVIC Z , Brozyna AA, Tuckey RC, Kim TK, et al
   High basal NF-kappaB activity in nonpigmented melanoma cells is associated with an enhanced sensitivity to vitamin D3 derivatives.
   Br J Cancer. 2011 Nov 17. doi: 10.1038/bjc.2011.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   
7. JOURNE F , Boufker HI, Van Kempen L, Galibert MD, et al
   TYRP1 mRNA expression in melanoma metastases correlates with clinical outcome.
   Br J Cancer. 2011 Nov 1. doi: 10.1038/bjc.2011.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   October 2011
8. KEIDAR M , Walk R, Shashurin A, Srinivasan P, et al
   Cold plasma selectivity and the possibility of a paradigm shift in cancer therapy.
   Br J Cancer. 2011;105:1295-301.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   
9. JOHNSON KJ , Carozza SE, Chow EJ, Fox EE, et al
   Birth characteristics and childhood carcinomas.
   Br J Cancer. 2011;105:1396-401.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   
10. FUKUDA H , Mochizuki S, Abe H, Okano HJ, et al
    Host-derived MMP-13 exhibits a protective role in lung metastasis of melanoma cells by local endostatin production.
    Br J Cancer. 2011 Oct 20. doi: 10.1038/bjc.2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    September 2011
11. GRIGNOL V , Fairchild ET, Zimmerer JM, Lesinski GB, et al
    miR-21 and miR-155 are associated with mitotic activity and lesion depth of borderline melanocytic lesions.
    Br J Cancer. 2011;105:1023-9.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
12. WEST EJ , Scott KJ, Jennings VA, Melcher AA, et al
    Immune activation by combination human lymphokine-activated killer and dendritic cell therapy.
    Br J Cancer. 2011;105:787-95.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    August 2011
13. DE LUCA A , Lamura L, Strizzi L, Roma C, et al
    Expression and functional role of CRIPTO-1 in cutaneous melanoma.
    Br J Cancer. 2011 Aug 23. doi: 10.1038/bjc.2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
14. TAWBI HA , Villaruz L, Tarhini A, Moschos S, et al
    Inhibition of DNA repair with MGMT pseudosubstrates: phase I study of lomeguatrib in combination with dacarbazine in patients with advanced melanoma and other solid tumours.
    Br J Cancer. 2011 Aug 2. doi: 10.1038/bjc.2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    July 2011
15. O'DAY S , Pavlick A, Loquai C, Lawson D, et al
    A randomised, phase II study of intetumumab, an anti-alpha(v)-integrin mAb, alone and with dacarbazine in stage IV melanoma.
    Br J Cancer. 2011 Jul 12. doi: 10.1038/bjc.2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
16. EISEN T , Marais R, Affolter A, Lorigan P, et al
    Sorafenib and dacarbazine as first-line therapy for advanced melanoma: phase I and open-label phase II studies.
    Br J Cancer. 2011 Jul 12. doi: 10.1038/bjc.2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
17. GREMEL G , Ryan D, Rafferty M, Lanigan F, et al
    Functional and prognostic relevance of the homeobox protein MSX2 in malignant melanoma.
    Br J Cancer. 2011 Jul 5. doi: 10.1038/bjc.2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    June 2011
18. SIGALOTTI L , Fratta E, Parisi G, Coral S, et al
    Stability of BRAF V600E mutation in metastatic melanoma: new insights for therapeutic success?
    Br J Cancer. 2011 Jun 21. doi: 10.1038/bjc.2011.
    PubMed     Text format     Related articles   
    
    
    
    
19. BRAIG S , Wallner S, Junglas B, Fuchshofer R, et al
    CTGF is overexpressed in malignant melanoma and promotes cell invasion and migration.
    Br J Cancer. 2011 Jun 14. doi: 10.1038/bjc.2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
20. DEBLACAM C , Byrne C, Hughes E, McIlroy M, et al
    HOXC11-SRC-1 regulation of S100beta in cutaneous melanoma: new targets for the kinase inhibitor dasatinib.
    Br J Cancer. 2011 Jun 7. doi: 10.1038/bjc.2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    May 2011
21. CHIARION-SILENI V , Guida M, Ridolfi L, Romanini A, et al
    Central nervous system failure in melanoma patients: results of a randomised, multicentre phase 3 study of temozolomide- and dacarbazine- based regimens.
    Br J Cancer. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    March 2011
22. REUSCHENBACH M , Tran T, Faulstich F, Hartschuh W, et al
    High-risk human papillomavirus in non-melanoma skin lesions from renal allograft recipients and immunocompetent patients.
    Br J Cancer. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
23. GRAVELLS P , Hoh L, Canovas D, Rennie IG, et al
    Resistance of uveal melanoma to the interstrand cross-linking agent mitomycin C is associated with reduced expression of CYP450R.
    Br J Cancer. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
24. KHAN OA , Gore M, Lorigan P, Stone J, et al
    A phase I study of the safety and tolerability of olaparib (AZD2281, KU0059436) and dacarbazine in patients with advanced solid tumours.
    Br J Cancer. 2011;104:750-5.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
25. KUROSU T , Ohga N, Hida Y, Maishi N, et al
    HuR keeps an angiogenic switch on by stabilising mRNA of VEGF and COX-2 in tumour endothelium.
    Br J Cancer. 2011;104:819-29.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    February 2011
26. LIAO YH , Hsu SM, Yang HL, Tsai MS, et al
    Upregulated ankyrin repeat-rich membrane spanning protein contributes to tumour progression in cutaneous melanoma.
    Br J Cancer. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
27. WANG Y , Wang XY, Subjeck JR, Shrikant PA, et al
    Temsirolimus, an mTOR inhibitor, enhances anti-tumour effects of heat shock protein cancer vaccines.
    Br J Cancer. 2011;104:643-52.
    PubMed     Text format     Related articles   
    
    
    
    January 2011
28. MOHAMMED MZ , Vyjayanti VN, Laughton CA, Dekker LV, et al
    Development and evaluation of human AP endonuclease inhibitors in melanoma and glioma cell lines.
    Br J Cancer. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
29. LIN J , Goto Y, Murata H, Sakaizawa K, et al
    Polyclonality of BRAF mutations in primary melanoma and the selection of mutant alleles during progression.
    Br J Cancer. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    December 2010
30. AMATSCHEK S , Lucas R, Eger A, Pflueger M, et al
    CXCL9 induces chemotaxis, chemorepulsion and endothelial barrier disruption through CXCR3-mediated activation of melanoma cells.
    Br J Cancer. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
31. ARKENAU HT , Kefford R, Long GV
    Targeting BRAF for patients with melanoma.
    Br J Cancer. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    November 2010
32. BERTHIER-VERGNES O , Kharbili ME, de la Fouchardiere A, Pointecouteau T, et al
    Gene expression profiles of human melanoma cells with different invasive potential reveal TSPAN8 as a novel mediator of invasion.
    Br J Cancer. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    October 2010
33. KASPARIAN NA , McLoone JK, Meiser B, Butow PN, et al
    Skin cancer screening behaviours among individuals with a strong family history of malignant melanoma.
    Br J Cancer. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
34. DEVY J , Duca L, Cantarelli B, Joseph-Pietras D, et al
    Elastin-derived peptides enhance melanoma growth in vivo by upregulating the activation of Mcol-A (MMP-1) collagenase.
    Br J Cancer. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
35. DECONTI RC , Algazi AP, Andrews S, Urbas P, et al
    Phase II trial of sagopilone, a novel epothilone analog in metastatic melanoma.
    Br J Cancer. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    September 2010
36. MITRA A , Conway C, Walker C, Cook M, et al
    Melanoma sentinel node biopsy and prediction models for relapse and overall survival.
    Br J Cancer. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    August 2010
37. HASSEL JC , Sucker A, Edler L, Kurzen H, et al
    MGMT gene promoter methylation correlates with tolerance of temozolomide treatment in melanoma but not with clinical outcome.
    Br J Cancer. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    July 2010
38. DAMATO B
    Does ocular treatment of uveal melanoma influence survival?
    Br J Cancer. 2010;103:285-90.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    June 2010
39. PARAISO KH , Fedorenko IV, Cantini LP, Munko AC, et al
    Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy.
    Br J Cancer. 2010;102:1724-30.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    May 2010
40. DOHERTY VR , Brewster DH, Jensen S, Gorman D, et al
    Trends in skin cancer incidence by socioeconomic position in Scotland, 1978-2004.
    Br J Cancer. 2010;102:1661-4.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
41. MURCHIE P , Nicolson MC, Hannaford PC, Raja EA, et al
    Patient satisfaction with GP-led melanoma follow-up: a randomised controlled trial.
    Br J Cancer. 2010;102:1447-55.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
42. LECIS D , Drago C, Manzoni L, Seneci P, et al
    Novel SMAC-mimetics synergistically stimulate melanoma cell death in combination with TRAIL and Bortezomib.
    Br J Cancer. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
43. FRANCKEN AB , Hoekstra-Weebers JW, Hoekstra HJ
    Is GP-led follow-up feasible?
    Br J Cancer. 2010;102:1445-6.
    PubMed     Text format     Related articles   
    
    
    
    April 2010
44. RUSTIN GJ , Shreeves G, Nathan PD, Gaya A, et al
    A Phase Ib trial of CA4P (combretastatin A-4 phosphate), carboplatin, and paclitaxel in patients with advanced cancer.
    Br J Cancer. 2010;102:1355-60.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
45. SHU X , Ji J, Li X, Sundquist J, et al
    Cancer risk in patients hospitalised for Graves' disease: a population-based cohort study in Sweden.
    Br J Cancer. 2010;102:1397-9.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
46. STAUDT M , Lasithiotakis K, Leiter U, Meier F, et al
    Determinants of survival in patients with brain metastases from cutaneous melanoma.
    Br J Cancer. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
47. HANDOLIAS D , Hamilton AL, Salemi R, Tan A, et al
    Clinical responses observed with imatinib or sorafenib in melanoma patients expressing mutations in KIT.
    Br J Cancer. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    March 2010
48. WALSH N , Kennedy S, Larkin AM, Tryfonopoulos D, et al
    Membrane transport proteins in human melanoma: associations with tumour aggressiveness and metastasis.
    Br J Cancer. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
49. DEBERGH I , Van Damme N, Pattyn P, Peeters M, et al
    The low-molecular-weight heparin, nadroparin, inhibits tumour angiogenesis in a rodent dorsal skinfold chamber model.
    Br J Cancer. 2010;102:837-43.
    PubMed     Text format     Related articles    Abstract available
    
    
    

Thank you for your interest in scientific medicine.

Amedeo is a Flying Publisher website.    Design: